Miconazole%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

# Miconazole Vaginal Pessary ## Overview Miconazole is an imidazole antifungal agent. This request pertains to a miconazole vaginal pessary. ## Primary Indications Treatment of vulvovaginal candidiasis (yeast infection). ## Adult Dosing * **100 mg pessary:** Insert one pessary vaginally at bedtime for 7 consecutive nights. * **200 mg pessary:** Insert one pessary vaginally at bedtime for 3 consecutive nights. * **High-strength (e.g., 1200 mg) pessary:** Insert one pessary vaginally as a single dose. ## Pediatric Dosing Data for pediatric use of miconazole vaginal pessaries is limited. Use in pediatric patients, particularly those under 12 years, should be based on clinical judgment and consultation with a healthcare provider. ## Dose Adjustments No dose adjustments are typically required for renal or hepatic impairment with vaginal administration. ## Contraindications Hypersensitivity to miconazole or any component of the formulation. ## Adverse Effects Common: Vaginal burning, itching, irritation. Less common: Headache, rash. ## Key Drug Interactions * **Warfarin:** Miconazole, particularly oral formulations, can inhibit CYP2C9, increasing warfarin levels and bleeding risk. While systemic absorption from vaginal pessaries is generally low, caution is advised, especially with prolonged use or in patients with impaired barrier function. Monitor INR closely if concomitant warfarin use. * **Other CYP3A4 substrates:** Systemic absorption could theoretically affect other CYP3A4 substrates, but this is unlikely with typical vaginal use. ## Monitoring * Symptom resolution. * Monitor for signs of local irritation or allergic reaction. ## Clinical Pearls * Complete the full course of therapy as directed, even if symptoms improve sooner. * Avoid sexual intercourse during treatment to prevent potential irritation or reinfection. * Pessaries may weaken latex condoms and diaphragms; consider alternative contraception during treatment. * If symptoms persist after completing treatment or worsen, re-evaluate diagnosis and consider alternative therapy. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before making clinical decisions.*